Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA said the results of the newly cleared blood test must be assessed in conjunction with other clinical information from a patient.

The U.S. Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

Eli Lilly says a new starting dose regimen for ... a potentially serious side effect known as ARIA-E, according to the company. The data comes from the phase 3b TRAILBLAZER-ALZ 6 study, which ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

With threats of additional tariffs targeting prescription drugs, pharmacists worry that costs will soar for medications.